2月27日，根据香港交易所公告，美格智能技术股份有限公司（002881.SZ）正式启动H股全球发售，拟 发行3500万股H股，发售价上限为每股28.86港元，预计募资至多约10亿港元。公司H股预计将于3月10 日在香港联交所主板挂牌交易，中金公司担任独家保荐人。 本次全球发售中，香港公开发售部分为350万股，占比10%；国际发售部分为3150万股，占比90%。每 手买卖单位为100股。招股期为2月27日至3月5日，预期定价日为3月6日。按最高发售价计算并假设发售 量调整权未获行使，公司预计所得款项净额约为9.445亿港元。 在资金用途方面，根据公司公告，约55%的募集资金将用于提升研发及创新能力，约15%用于偿还银行 借款以优化财务结构，约10%用于拓展海外销售网络，约10%用于战略投资及收购，其余约10%用于营 运资金及一般公司用途。 作者：观察君 美格智能是一家以智能模组（尤其是高算力智能模组）为核心的无线通信模组及解决方案提供商，产品 广泛应用于泛物联网、智能网联车及无线宽带领域。根据弗若斯特沙利文的数据，2024年按无线通信模 组业务收入计，公司在全球排名第四，市场份额为6.4%。财务数据显示，202 ...

Group 1: IPO Market Activity - The Hong Kong IPO market remained active from February 9 to 15, with 18 companies submitting listing applications, 1 company passing the hearing, and 2 companies completing their public offerings [1] - Six new stocks were listed during this period, with several A-share listed companies initiating "A+H" dual listing processes [1] Group 2: Notable Listings - Haizhi Technology Group (02706.HK) was listed on February 13, with an initial price of HKD 27.06 per share, closing at HKD 92.60 on its first day, marking a 242.20% increase and a market capitalization exceeding HKD 37 billion [4] - The company received a subscription rate of 5065.06 times during the public offering phase and raised approximately HKD 655.4 million [4] Group 3: Company Submissions - Siyuan Electric (002028.SZ) submitted its listing application to the Hong Kong Stock Exchange on February 11, with CITIC Securities as the sole sponsor. The company ranks third among private enterprises in China's power distribution and control equipment market, holding a market share of 3.5% [3] - Other companies that submitted applications include Jingxin Pharmaceutical (002020.SZ) and Xinlitai (002294.SZ), both focusing on central nervous and cardiovascular diseases [3] Group 4: Market Trends - The IPO submissions included companies from various sectors, such as VDL Technology in consumer electronics, Helian Group in bulk commodity services, and Hai Rou Innovation in warehouse robotics [3] - In the biopharmaceutical sector, multiple companies, including Vimo Bio, Yimufeng Bio, Plai Medical, and Noling Bio, also submitted applications [3]

Core Insights - Hong Kong's IPO fundraising reached a record high of $37.4 billion in 2025, surpassing the total of the previous three years combined, marking a return to the top of the global IPO market after four years [1][3] - The surge in IPOs is attributed to explosive growth in listed companies, with 612 applications received and 119 successful listings, a 68% increase year-on-year [3][5] - Key sectors driving this growth include pharmaceuticals and technology, with significant participation from companies already listed on A-shares [3][5] IPO Performance - The top 10 IPOs in Hong Kong raised a total of approximately 142.5 billion HKD, accounting for about 50% of the total fundraising for the year [6][7] - Notable IPOs include CATL, which raised over 41 billion HKD, and Zijin Mining, which raised approximately 28.7 billion HKD [6][7] - The average first-day gain for new listings was significant, with the highest being 363.75% for Nobikang [10][12] Market Trends - The proportion of IPOs with a market capitalization exceeding 10 billion HKD reached 56%, significantly higher than the 30% average over the past five years [5] - The IPO market showed signs of confidence, with a record low first-day failure rate of 28.83% [5] - A total of 19 companies achieved dual listings (A+H), the highest in recent years, primarily in information technology and new consumption sectors [16][18] Industry Highlights - The emergence of "first stocks" in various sectors, such as high-end tea and AI, reflects the market's recognition of leading companies in niche areas [19][20] - The IPO market remains active into 2026, with 21 companies already listed by February, raising a total of 791.17 million HKD, indicating a 1220% increase [29][30] - Predictions for 2026 suggest the potential for 150 to 200 new listings, with fundraising expected to exceed 300 billion HKD, reinforcing Hong Kong's position as a leading global IPO market [29][30]

Core Viewpoint - The recent surge in "A+H" listings has seen over 100 A-share companies at various stages of seeking listings in Hong Kong, with a notable presence of biopharmaceutical companies like Kexing Pharmaceutical, which has submitted its application for dual listing [1][2]. Company Overview - Kexing Pharmaceutical, established in 1989 and restructured into a joint-stock company in 2019, is headquartered in Jinan, Shandong [4][3]. - The actual controller of the company, Deng Xueqin, holds 56.27% of the voting rights as of October 2025 [5]. - The board of directors consists of eight members, including four executive directors [6]. Financial Performance - Kexing Pharmaceutical's revenue has fluctuated in recent years, with figures of 1.31 billion, 1.26 billion, 1.40 billion, and 700 million RMB reported for 2022, 2023, 2024, and the first half of 2025, respectively [25]. - The company achieved profitability in 2024, with net profits of 27.05 million RMB and 78.96 million RMB in the first half of 2025 [26]. - Sales expenses have been high, totaling 2.369 billion RMB over three and a half years, while R&D expenses were approximately 788 million RMB, accounting for 16.8% of total revenue [27]. Product Portfolio - Kexing Pharmaceutical has established a product matrix consisting of commercialized products, a research pipeline, and introduced products [9][12]. - The company has four main commercialized products, including SINOGEN, which holds a 55.2% market share in China's short-acting interferon α1b market [10][11]. - The revenue from these products for the years 2022, 2023, 2024, and the first half of 2025 was 1.314 billion, 1.254 billion, 1.392 billion, and 680 million RMB, respectively [12]. Research and Development - Kexing Pharmaceutical has a pipeline of 5 products in clinical stages and 10 in preclinical stages, focusing on oncology, autoimmune diseases, and degenerative diseases [13][18]. - The company has developed a "3KX technology platform" to enhance the R&D process, integrating various advanced technologies [14]. - The most advanced products in the pipeline are GB05 and GB-K02, both currently in Phase III clinical trials [19][20]. Market Position and Challenges - The company is facing challenges due to a lack of blockbuster products and a relatively weak R&D capability compared to other biotech firms [30]. - The sales team may struggle with centralized management due to a dispersed pipeline layout, leading to higher sales expenses [30].

Group 1 - The company Tongcheng New Materials (603650) plans to list on the Hong Kong Stock Exchange to achieve a dual listing (A+H), aiming to expand financing channels and international presence [1] - The company's electronic materials business is accelerating growth, with semiconductor photoresists becoming a core growth driver, and the CMP polishing pad project has entered the commercialization stage [1] Group 2 - In the first three quarters of 2025, the company reported revenue of 2.523 billion yuan, a year-on-year increase of 4.06%, and a net profit attributable to shareholders of 494 million yuan, up 12.65%, although the net profit growth rate has slowed compared to 2024 [3] - The gross profit margin has steadily increased to 25.2%, but trade receivables have risen to 730 million yuan, with turnover days extending to 75 days, indicating a need to monitor collection risks [3] Group 3 - The company has consistently issued large dividends in recent years, with dividends of 48 million yuan, 352 million yuan, and 298 million yuan for the years 2023 to the first three quarters of 2025, respectively [4] - During the same period, financial costs accounted for approximately 3% of total revenue, primarily from interest-bearing borrowings, which may erode profits [4] Group 4 - Shareholder Yutong Investment plans to reduce holdings, cashing out approximately 659 million yuan by 2025, reducing its shareholding ratio to 1.91% [2] - As of February 2, 2026, the financing balance reached 793 million yuan, reflecting a high level of capital activity [2]

Core Viewpoint - Tongcheng New Materials (彤程新材) is applying for a dual listing on the A+H stock markets, facing slowing profit growth and declining average selling prices in its business segments, with trade receivables rising to 730 million RMB [1][3]. Financial Performance - For the fiscal years 2023 to 2025, the company's revenue figures are 2.944 billion RMB, 3.270 billion RMB, and 2.523 billion RMB respectively, with net profits of 407 million RMB, 517 million RMB, and 494 million RMB, showing significant deceleration in growth rates of 36.37%, 27.10%, and 12.65% [3][6]. - The overall gross profit margins remained relatively stable at approximately 23.3%, 24.4%, and 25.2%, with gross profits of about 685 million RMB, 796 million RMB, and 634 million RMB [8]. Business Segments - The company operates in three main segments: electronic materials, tire rubber additives, and fully biodegradable materials. The tire rubber additives segment is the largest revenue contributor, accounting for 77.5%, 74.7%, and 69.7% of total revenue in the respective periods [6][7]. - The electronic materials segment's revenue share increased from 19.1% to 27.8% over the same period, with average selling prices rising from 44,300 RMB to 53,900 RMB [7]. Trade Receivables and Inventory - Trade receivables have increased to 730 million RMB, with turnover days rising from 71 to 75 days, indicating potential collection challenges [8][9]. - Inventory levels have also increased, with amounts of 431 million RMB, 486 million RMB, and 511 million RMB, and inventory turnover days extending from 68 to 73 days [10]. Market Performance - As of February 6, the company's stock price rose by 1.42% to 55.55 RMB per share, with a total market capitalization of approximately 34.225 billion RMB, reflecting a more than 60% increase in stock price over the past year [11].

Core Viewpoint - Dongpeng Beverage has successfully completed its "A+H" dual listing on the Hong Kong Stock Exchange, becoming the first functional beverage brand in China to achieve this milestone, which has garnered significant industry attention [1][3]. Group 1: Company Overview - Dongpeng Beverage focuses on the functional beverage sector and has been the market leader in China by sales volume for four consecutive years since 2021, with market share increasing from 15.0% to a projected 26.3% by 2024 [3]. - The company’s latest market capitalization in A-shares has surpassed 1400 billion, and the IPO in Hong Kong raised nearly 10 billion, marking the largest IPO in the Asian beverage sector since 2020 [1][3]. Group 2: Market Performance - The IPO was priced at 248 HKD per share, resulting in an opening market capitalization of approximately 110 billion HKD [1]. - Despite a lackluster debut with the stock price dipping below the issue price, the long-term growth potential of Dongpeng Beverage is viewed positively, as the functional beverage market in China has experienced a compound annual growth rate of 8.3% over the past five years, significantly outpacing the overall soft drink market growth of 4.7% [12]. Group 3: Investment and Future Plans - The company has attracted 15 prominent cornerstone investors, including global giants like Qatar Investment Authority and Temasek, with a total subscription amounting to 640 million USD, reflecting strong market confidence in Dongpeng Beverage's growth potential [3]. - The funds raised from the IPO will be allocated as follows: approximately 36.0% for capacity expansion and supply chain upgrades, 15.0% for brand building, 11.0% for national strategy implementation, 12.0% for overseas market expansion, 10.0% for digital transformation, 6.0% for product development, and 10.0% for working capital [14]. Group 4: Strategic Partnerships - The company has established a significant partnership with singer Han Hong, who has become the first brand ambassador for Dongpeng's "Dongpeng Daka" line, marking a transition from a philanthropic relationship to a commercial alliance [9][10].

Group 1 - The Hong Kong stock market experienced a significant resurgence in 2025, with 114 new companies listed and total fundraising exceeding 286.3 billion HKD, reclaiming the title of the world's top IPO fundraising hub after six years [3][4] - The number of IPOs increased by 63% and total fundraising surged by 228% compared to 2024, highlighting a remarkable recovery in market activity [3][4] - The "A+H" dual listing model saw explosive growth, with 19 new companies adopting this model, raising a total of over 139.9 billion HKD, nearly half of the total IPO fundraising for the year [4] Group 2 - Leading companies like CATL contributed significantly to the fundraising, with CATL alone raising approximately 41.0 billion HKD, accounting for 14% of the total [4][5] - The fundraising strategies of these companies indicate a clear internationalization direction, with CATL planning to use about 90% of its funds for a battery factory in Hungary [5] - International institutional investors showed increased recognition of Chinese core assets, with cornerstone investors in CATL's IPO subscribing to 66% of the total issuance [5] Group 3 - Chinese investment banks demonstrated strong dominance in the IPO advisory market, with 43 sponsoring institutions involved in 114 IPOs, and CICC, CITIC Securities, and Huatai International leading the market [6] - CICC participated in 53 projects, achieving a market coverage rate of 45%, indicating a growing competitive edge for Chinese investment banks on the international stage [6] Group 4 - Deloitte forecasts optimistic growth for the Hong Kong IPO market in 2026, predicting around 160 new listings and a fundraising scale of no less than 300 billion HKD [7] - The focus will be on various sectors, including technology, media, telecommunications, healthcare, and international companies, indicating a diverse range of upcoming IPO projects [7] - The Hong Kong government anticipates economic growth of 3.2% in 2025, with plans to enhance financial market advantages and explore new opportunities in fixed income, green finance, and commodity trading [7]

Core Viewpoint - The article highlights the impressive turnaround of Baiwei Storage under the leadership of Chairman Sun Chengsi, projecting significant profit growth driven by the rising demand for storage chips, particularly in the AI sector. The company aims for an IPO in Hong Kong to expand its operations further [5][9][25]. Group 1: Company Performance - Baiwei Storage is expected to achieve a net profit of 850-1,000 million yuan in 2025, representing a year-on-year increase of 400-500% [5][12]. - The company reported a profit of over 1 billion yuan in just six months, showcasing its rapid recovery and growth [6][12]. - The stock price reached a new high of 145.9 yuan per share on January 14, 2025, indicating strong market confidence [25]. Group 2: Market Dynamics - The storage product prices are projected to follow a "U-shaped" curve, declining until Q1 2025 and then recovering, which will boost sales revenue and gross margins [14]. - The demand for storage is being driven by AI applications, particularly in AI inference, edge AI, and emerging AI applications [17]. - Baiwei's products are being integrated into various sectors, including robotics and consumer electronics, with notable clients like Lenovo and Xiaomi [18][19]. Group 3: Leadership and Strategy - Sun Chengsi, who took over the company at the age of 27, has been instrumental in transforming Baiwei's business model from ODM to a more integrated R&D and packaging approach [7][21]. - The company has established partnerships with major semiconductor manufacturers and has focused on enhancing its packaging and testing capabilities [21][29]. - Baiwei is the only independent storage solution provider globally with wafer-level packaging capabilities, which enhances its competitive edge [29]. Group 4: Future Outlook - Baiwei plans to expand its production capacity significantly, with a fundraising target of approximately 1.9 billion yuan aimed at enhancing its manufacturing capabilities [32]. - The company anticipates that revenue from AI glasses will reach about 106 million yuan in 2024, with expectations of over 500% growth in 2025 [31]. - The management is preparing for a dual listing in Hong Kong, which will further support its growth ambitions [25][26].

Core Viewpoint - The company Guangdong Lingyi iTech Limited (002600.SZ) announced a share reduction plan by its actual controller and chairman, Zeng Fangqin, amidst significant cash acquisitions and a dual listing strategy [2][3]. Group 1: Share Reduction Plan - Zeng Fangqin plans to reduce his holdings by up to 36 million shares, representing 0.49% of the company's total share capital, through block trading over three months starting from February 7, 2026 [3]. - The reason for the reduction is stated as "personal funding needs," with an estimated market value exceeding 500 million yuan based on the closing price of 16.51 yuan per share [3]. - The company emphasizes that this reduction will not affect its control or governance structure [3]. Group 2: Recent Acquisitions - The company has made a significant cash acquisition of 2.404 billion yuan to purchase 96.15% of Zhejiang Xianglong Machinery, which specializes in automotive parts [4]. - This acquisition marks a strategic shift from being a Tier 2 supplier to a Tier 1 supplier in the automotive industry, indicating the company's ambition to diversify beyond consumer electronics [4]. Group 3: Financial Performance and Debt Pressure - As of the end of Q3 2025, the company faced increased short-term borrowing, indicating potential short-term repayment pressures [5]. - The reduction in shareholding may reflect shareholder concerns regarding cash flow amidst rapid expansion [5]. Group 4: Dual Listing Strategy - The company is actively pursuing a dual listing, having submitted an application for H-share listing on the Hong Kong Stock Exchange, aiming to enhance its capital structure and support global expansion [6]. - The funds raised from the H-share listing are intended for overseas production bases, AI terminal development, and strategic investments [6]. - For the first three quarters of 2025, the company reported revenues of 37.59 billion yuan, a year-on-year increase of 19.25%, and a net profit of 1.941 billion yuan, up 37.66% [6].